Apimeds Pharmaceuticals US (APUS) Short-term Investments (2025)

Apimeds Pharmaceuticals US (APUS) reported Short-term Investments of $2.0 million for Q4 2025.

Apimeds Pharmaceuticals US (APUS) Short-term Investments (2025) Analysis & Trends

Apimeds Pharmaceuticals US has reported Short-term Investments for 1 years, with the latest figure at $2.0 million in Q4 2025.

  • For the quarter ending Q4 2025, Short-term Investments changed N/A year-over-year to $2.0 million; the trailing twelve-month figure through Dec 2025 stood at $2.0 million (changed N/A YoY), and the FY2025 full-year result was $2.0 million, changed N/A from the prior year.
  • Short-term Investments for Q4 2025 stood at $2.0 million.
  • The five-year high for Short-term Investments was $2.0 million in Q4 2025, with the low at $2.0 million in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Teva Pharmaceutical Industries 39.97 Bn 36.23 Bn 1.97 Bn
2 Zoetis 33.59 Bn 31.65 Bn 1.62 Bn
3 United Therapeutics 23.75 Bn 21.60 Bn 648.10 Mn
4 Neurocrine Biosciences 16.10 Bn 14.78 Bn 800.70 Mn
5 Aurora Cannabis 15.56 Bn 15.47 Bn 21.72 Mn
6 Elanco Animal Health 12.04 Bn 11.61 Bn 785.00 Mn
7 Alkermes 7.36 Bn 6.84 Bn -116.06 Mn
8 Lantheus Holdings 6.74 Bn 6.24 Bn 230.92 Mn
9 Liquidia 6.27 Bn 6.04 Bn 121.79 Mn
10 Apimeds Pharmaceuticals US 14.04 Mn 10.40 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2025 2.00 Mn